Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes

Reference

• Alexandre E, Calm M, Viollon-Abadie C, Meyer N, Heyd B, Mantion G, Cinqualbre J, David P, Jaeck D, Richert L. 2002a. Influence of pre-, intra- and post-operative parameters of donor liver on the outcome of isolated human hepatocytes. Cell and Tissue Banking 3:223–233.
   Google Scholar
• Alexandre E, Viollon-Abadie C, David P, Gandillet A, Coassolo P, Heyd B, Mantion G, Wolf P, Bachellier P, Jaeck D, Richert L. 2002b. Cryopreservation of adult human hepatocytes obtained from resected liver biopsies. Cryobiology 44:103–113.
   PubMed Web of Science ®Google Scholar
• Allonen H, Ziegler G, Klotz U. 1981. Midazolarn kinetics. Clinical and Pharmacological Therapeutics 30:653–661.
   PubMed Web of Science ®Google Scholar
• Amrein R, Cano JP, Eckert M, Coassolo P. 1981. [Pharmacokinetics of midazolarn after ix. administration]. Arzneimittelforschung 31:2202–2205.
   PubMed Web of Science ®Google Scholar
• Asali, LA, Brown, KF. 1984. Naloxone protein binding in adult and foetal plasma. European Journal of Clinical Pharmacology 27:459–463.
   PubMed Web of Science ®Google Scholar
• Bachmann K, Byers J, Ghosh R. 2003. Prediction of in vivo hepatic clearance from in vitro data using cryopreserved human hepatocytes. Xenobiotica 33:475–483.
   PubMed Web of Science ®Google Scholar
• Blanchard N, Richert L, Notter B, Delobel F, David P, Coassolo P, Lave T. 2004. Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. European Journal of Pharmaceutical Sciences 23:189–199.
   PubMed Web of Science ®Google Scholar
• Burczynski FJ, Cai ZS, Moran JB, Forker EL. 1989. Palmitate uptake by cultured hepatocytes: albumin binding and stagnant layer phenomena. American Journal of Physiology 257:G584–G593.
   Google Scholar
• Fabre G, Combalbert J, Berger Y, Cano JP. 1990. Human hepatocytes as a key in vitro model to improve preclinical drug development. European Journal of Drug Metabolism and Pharmacokinetics 15:165–171.
   PubMed Web of Science ®Google Scholar
• Forker EL, Luxon BA, Snell M, Shurmantine WO. 1982. Effect of albumin binding on the hepatic transport of rose Bengal: surface-mediated dissociation of limited capacity. Journal of Pharmacology and Experimental Therapeutics 223:342–347.
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, Donato MT, Castell JV, Jover R. 2003. Human hepatocytes as a tool for studying toxicity and drug metabolism. Current Drug Metabolism 4:292–312.
   PubMed Web of Science ®Google Scholar
• Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. 1994. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemical Pharmacology 47:1643–1653.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ. 1980. Pharmacokinetic comparisons. Psychosomatics 21:9–14.
   PubMedGoogle Scholar
• Greenblatt DJ, Shader RI, Divoll M, Harmatz JS. 1981. Benzodiazepines: a summary of pharmacokinetic properties. British Journal of Clinical Pharmacology 11\(Suppl. 1):11S–16S.
   Google Scholar
• Lave T, Coassolo P, Reigner B. 1999. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clinical Pharmacokinetics 36:211–231.
   PubMed Web of Science ®Google Scholar
• Lave T, Coassolo P, Ubeaud G, Brandt R, Schmitt C, Dupin S, Jaeck D, Chou RC. 1996. Interspecies scaling of bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling. Pharmacology Research 13:97–101.
   PubMed Web of Science ®Google Scholar
• Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P. 1997. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. Journal of Pharmaceutical Sciences 86:584–590.
   PubMed Web of Science ®Google Scholar
• LeCluyse EL. 2001. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. European Journal of Pharmaceutical Sciences 13:343–368.
   PubMed Web of Science ®Google Scholar
• Li AP. 2001. Screening for human ADME/Tox drug properties in drug discovery. Drug Discovery Today 6:357–366.
   PubMed Web of Science ®Google Scholar
• Mistry M, Houston JB. 1987. Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metabolism and Disposition 15:710–717.
   PubMed Web of Science ®Google Scholar
• Olinga P, Merema M, Slooff MJ, Meijer DK, Groothuis GM. 1997. Influence of 48 hours of cold storage in University of Wisconsin organ preservation solution on metabolic capacity of rat hepatocytes. Journal of Hepatology 27:738–743.
   PubMed Web of Science ®Google Scholar
• Ponsoda X, Pareja E, Gomez-Lechon MJ, Fabra R, Carrasco E, Trullenque R, Castell JV. 2001. Drug biotransformation by human hepatocytes. In vitro/in vivo metabolism by cells from the same donor. Journal of Hepatology 34:19–25.
   Google Scholar
• Richert L, Alexandre E, Lloyd T, Orr S, Viollon-Abadie C, Patel R, Kingston S, Berry D, Heyd B, Mantion G, Jaeck D. 2004. Tissue collection, transport and isolation procedures required to optimise human hepatocyte isolation from waste liver surgical resections. A multi-laboratory study. Liver International 24:371–378.
   Google Scholar
• Richert L, Lamboley C, Viollon-Abadie C, Grass P, Hartmann N, Laurent S, Heyd B, Mantion G, Chibout SD, Staedtler F. 2003. Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes. Toxicology and Applied Pharmacology 191:130–146.
   PubMed Web of Science ®Google Scholar
• Roux S, Breu V, Ertel SI, Clozel M. 1999. Endothelin antagonism with bosentan: a review of potential applications. Journal of Molecular Medicine 77:364–376.
   PubMed Web of Science ®Google Scholar
• Sahi J, Hamilton G, Sinz M, Barros S, Huang SM, Lesko 14, LeCluyse EL. 2000. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica 30:273–284.
   PubMed Web of Science ®Google Scholar
• Shibata Y, Takahashi H, Ishii Y. 2000. A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metabolism and Disposition 28:1518–1523.
   PubMed Web of Science ®Google Scholar
• Shibata Y, Takahashi H, Chiba M, Ishii Y. 2002. Prediction of hepatic clearance and availability by cryopre-served human hepatocytes: an application of serum incubation method. Drug Metabolism and Disposition 30:892–896.
   PubMed Web of Science ®Google Scholar
• Skett P, Tyson C, Guillouzo A, Maier P. 1995. Report on the international workshop on the use of human in vitro liver preparations to study drug metabolism in drug development. Held at Utrecht, The Netherlands, 6-8 September 1994. Biochemical Pharmacology 50:280–285.
   PubMed Web of Science ®Google Scholar
• Smith MT, Eadie MJ, Brophy TO. 1981. The pharmacokinetics of midazolam in man. European Journal of Clinical Pharmacology 19:271–278.
   PubMed Web of Science ®Google Scholar
• Steinberg P, Fischer T, Kiulies S, Biefang K, Platt KL, Oesch F, Bottger T, Bulitta C, Kempf P, Hengstler J. 1999. Drug metabolizing capacity of cryopreserved human, rat, and mouse liver parenchymal cells in suspension. Drug Metabolism and Disposition 27:1415–1422.
   PubMed Web of Science ®Google Scholar
• Ubeaud G, Schmitt C, Jaeck D, Lave T, Coassolo P. 1995. Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica 25:1381–1390.
   PubMed Web of Science ®Google Scholar
• Van Giersbergen PL, Treiber A, Clozel M, Bodin F, Dingemanse J. 2002. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clinical and Pharmacological Therapeutics 71:253–262.
   PubMed Web of Science ®Google Scholar
• Wahlstrom A, Persson K, Rane A. 1989. Metabolic interaction between morphine and naloxone in human liver. A common pathway of glucuronidation? Drug Metabolism and Disposition 17:218–220.
   PubMed Web of Science ®Google Scholar
• Waring JF, Ciurlionis R, Jolly RA, Heindel M, Gagne G, Fagerland JA, Ulrich RG. 2003. Isolated human hepatocytes in culture display markedly different gene expression patterns depending on attachment status. Toxicology In Vitro 17:693–701.
   PubMed Web of Science ®Google Scholar
• Weaver RJ. 2001. Assessment of drug—drug interactions: concepts and approaches. Xenobiotica 31:499-538. Weinstein SH, Pfeffer M, Schor JM, Franklin L, Mintz M, Tutko ER. 1973. Absorption and distribution of naloxone in rats after oral and intravenous administration. Journal of Pharmaceutical Sciences 62:1416–1419.
   Google Scholar
• Zuegge J, Schneider G, Coassolo P, Lave T. 2001. Prediction of hepatic metabolic clearance: comparison and assessment of prediction models. Clinical Pharmacokinetics 40:553–563.
   PubMed Web of Science ®Google Scholar